Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | ATM | Q13315 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1326560 | 0.89 | ALDH1A1 (0.44) | LMNAKMT2APOLBGPBAR1ALDH1A1 | |
| SCHEMBL9766168 | 0.82 | ALDH1A1 (0.40) | LMNASMN1; SMN2KMT2APOLBGPBAR1 | |
| SCHEMBL19900445 | 0.77 | POLB (0.40) | KMT2APOLBALDH1A1HPGDMAPT | |
| SCHEMBL1086256 | 0.73 | NPC1 (0.45) | SMN1; SMN2KMT2AGPBAR1MEN1MAPT | |
| SCHEMBL1086652 | 0.73 | PTGS1 (0.47) | LMNASMN1; SMN2KMT2APOLBGPBAR1 | |
| SCHEMBL11911198 | 0.73 | LMNA (0.57) | LMNASMN1; SMN2KMT2APOLBGPBAR1 | |
| SCHEMBL11368118 | 0.73 | LMNA (0.57) | LMNASMN1; SMN2KMT2APOLBGPBAR1 | |
| SCHEMBL14363623 | 0.71 | L3MBTL1 (0.50) | LMNASMN1; SMN2KMT2AGPBAR1ALDH1A1 | |
| SCHEMBL10774901 | 0.71 | SMN1; SMN2 (0.58) | LMNASMN1; SMN2KMT2APOLBGPBAR1 | |
| SCHEMBL12603540 | 0.70 | SMN1; SMN2 (0.45) | LMNASMN1; SMN2KMT2APOLBGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1618098-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2014-11-19 | — | — | EP | claimed |
| US-8048890-B2 | Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | claimed |
| US-7951815-B2 | Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2011-05-31 | — | — | US | claimed |
| JP-4663982-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| EP-1730147-B1 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | GRUENENTHAL GMBH (DE) | 2010-02-03 | — | — | EP | claimed |
| WO-2005095402-A9 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | GRUENENTHAL GMBH (DE) | 2009-06-11 | — | — | WO | claimed |
| US-7304080-B2 | E.g., 3-[5-(2-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | claimed |
| US-7271192-B2 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | GRUENENTHAL GMBH (DE) | 2007-09-18 | — | — | US | claimed |
| EP-1451177-B1 | SUBSTITUTED 2-PYRROLIDINE-2-YL-1H-INDOLE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | GRUENENTHAL GMBH (DE) | 2007-03-21 | — | — | EP | claimed |
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | claimed |
| WO-1993011131-A1 | CEPHALOSPORIN COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1993-06-10 | — | — | WO | claimed |
| US-5064649-A | CEPHALOSPORIN DERIVATIVES | BEECHAM GROUP P.L.C. (GB) | 1991-11-12 | — | — | US | claimed |
| EP-0359536-A2 | Cephalosporin compounds, process for their preparation and pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1990-03-21 | — | — | EP | claimed |
| EP-0354757-A2 | Cephalosporins and homologous compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1990-02-14 | — | — | EP | claimed |
| EP-0000891-B1 | SYNERGISTIC COMBINATIONS OF PENICILLINS AND ANTIBIOTIC AGENTS CONTAINING THEM | BAYER AG (DE) | 1980-01-09 | — | — | EP | claimed |
| US-4179511-A | Antibacterial 3-(5-tetrazolyl) penam compounds | PFIZER INC. (US) | 1979-12-18 | — | — | US | claimed |
| US-4168263-A | HAVING PENICILLOYL RESIDUES BOUND TO SIDE CHAINS | HOFFMANN-LA ROCHE INC. (US) | 1979-09-18 | — | — | US | claimed |
| EP-0000891-A1 | Synergistic combinations of penicillins and antibiotic agents containing them | BAYER AG (DE) | 1979-03-07 | — | — | EP | claimed |
| US-4143039-A | ANTIBACTERIAL 3-(5-TETRAZOLYL)PENAM COMPOUNDS | PFIZER INC. (US) | 1979-03-06 | — | — | US | claimed |
| US-4115385-A | PENICILLINS | PFIZER INC. (US) | 1978-09-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | SI, SSTR4, SLC10A2 | LMNA 3374/4885SMN1; SMN2 2139/4885KMT2A 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.